Identifying Prognostic Factors in Patients Receiving Tegafur-Uracil for Stage II Colon Cancer That Was Completely Removed By Surgery

NCT00898846 · clinicaltrials.gov ↗

COMPLETED

Status

1111

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: UFT adjuvant chemotherapy

Sponsor

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Collaborators

[object Object]